Suzanne Wood
New layout – Video
I'm a video Summary text to go with the video References 1 Cancer Discovery 10(4), 498-505 (2020) 2 Ettinger et al. Non-small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology, 497-530 (2022) Planchard et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up (2018) Sign [...]New layout – Press release
Ellipses Pharma features in the Guardian Innovations In Oncology supplement Chicago June 5, 2023: Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of new oncology treatments, today announces its intention to expedite further global clinical development of the next generation selective RET inhibitor (SRI) EP0031/A400 following the publication of ‘very [...]Ellipses Pharma featured in The Guardian: Innovations In Oncology
Ellipses Pharma features in the Guardian Innovations In Oncology supplement By leveraging a cloud-based platform, our SAG members provide invaluable scientific and clinical insights, validate asset selection, and offer unbiased input during the drug development process using real-world evidence. This collaborative effort ensures better decision-making, faster development, and increased chances of success in bringing potential [...]Ellipses Pharma announces intent to accelerate clinical programme following ‘encouraging’ data on next generation selective RET inhibitor
Ellipses Pharma announces intent to accelerate clinical programme following ‘encouraging’ data on next generation selective RET inhibitor Chicago June 5, 2023: Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of new oncology treatments, today announces its intention to expedite further global clinical development of the next generation selective RET inhibitor [...]Ellipses updates clinicians at ASCO on clinical trial programmes
Ellipses updates clinicians at Asco on clinical trial programmes Ellipses Pharma (“Ellipses”), a global company drug development company focused on accelerating innovative cancer medicines and treatments, today announces its leadership team will attend the forthcoming American Society of Oncology (ASCO) conference in Chicago where they will brief clinicians on the progress of clinical and pre-clinical [...]Ellipses Pharma featured in Nature Research
Ellipses Pharma featured in Nature Research Ellipses Pharma: maximizing KOL input to increase the success rate of oncology R&D. Read the full article here. EP0042 receives Orphan Drug Designation from the US Food and Drug Administration
EP0042 receives Orphan Drug Designation from the US Food and Drug Administration EP0042 is currently being investigated as a potential treatment option for patients with acute myeloid leukaemia Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug development model, today announces that [...]Expansion of Scientific Affairs Group
Expansion of Scientific Affairs Group More than 200 oncologists worldwide now involved in assessment and selection of potential treatments Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug development model, today announces a significant expansion of its Scientific Affairs Group (SAG). Ellipses [...]Ellipses Pharma Features in SCRIP
Ellipses Pharma features in SCRIP Ellipses Pharma has been featured in SCRIP. Read the full article here.